UC San Diego Health Moores Cancer Center shared a post on X:
“Congratulations to Moores Cancer Center member Rana McKay, MD, on co-authoring a landmark Nature study linking casdatifan’s EPO suppression to durable responses in advanced kidney cancer.
Dr. McKay:
‘This is a comprehensive analysis of the biology underlying the activity of casdatifan in clear cell kidney cancer… the degree of EPO suppression correlated with response, deepening our understanding of the effects of casdatifan and helping inform which patients derive the greatest benefit.'”
Title: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer
Authors: Toni K. Choueiri, Jamie Merchan, Amita Patnaik, Alexandra Drakaki, Brian I. Rini, Sun Young Rha, Jae Lyun Lee, Moshe C. Ornstein, Rohit Kumar, Clara Hwang, Yusra Shao, Se Hoon Park, Pedro C. Barata, Bradley A. McGregor, Paul Foster, Jianfen Chen, Melissa Eisen, Hunter Cole, Ben Weeder, Yinghui Guan, Jaskirat Singh, Angelo Kaplan, Soonweng Cho, Richard Markus, Omar Kabbarah and Rana R. McKay.
Other articles about UC San Diego on OncoDaily.
